Press Release

Filament Health Announces Clinical Trial Approval In Partnership With Psychiatric Centre Copenhagen

January 18, 2023

Danish psychiatric research hospital will study the effects of Filament’s natural psilocybin drug candidate for treating alcohol use disorder

Vancouver, British Columbia, January 18, 2023 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH)(FSE:7QS)(“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, today announced the approval of a clinical trial in partnership with Psychiatric Centre Copenhagen, Denmark's largest psychiatric centre known for being at the forefront of new treatment options that stem from recognized research. The trial, led by PhD student Mathias Ebbesen Jensen and Professor Anders Fink-Jensen, will study Filament’s natural psilocybin drug candidate for the treatment of alcohol use disorder (AUD) and was recently approved by the Danish Medicines Agency.

“Alcohol use disorder is a widespread issue for global public health and constitutes a major risk factor for disability and mortality,” said Anders Fink-Jensen, Clinical Professor at Psychiatric Centre Copenhagen and the trial’s Principal Investigator. “Clinical data suggests that psilocybin holds potential for the treatment of AUD, and our intention with this trial is to expand on those findings.”

Five percent of all deaths worldwide each year result from the harmful use of alcohol. With this trial, Psychiatric Centre Copenhagen will determine the effects of a single administration of 25 milligrams of psilocybin on alcohol use and study the extent to which the brain is affected by psilocybin. Filament Health produces natural psilocybin, extracted from magic mushrooms. The GMP-released drug candidate has been exported from Filament’s Metro Vancouver lab and has arrived at the clinical site in Copenhagen in preparation for the trial’s start.

“Psychiatric Centre Copenhagen is an internationally recognized psychiatric research institution,”said Benjamin Lightburn, Chief Executive Officer and Co-Founder of FilamentHealth. “We are proud that Mathias Ebbesen Jensen and Professor Fink-Jensen have selected Filament’s drug candidate for a clinical trial of this calibre and we’re pleased to support their important research.”

This is the third European clinical trial which has been approved to use Filament’s natural psilocybin. The trial in Copenhagen will begin next month.


Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at and on Twitter, Instagram, and LinkedIn.


Anna Cordon, Director of Communications778.245.9067



Certain statements and information contained herein may constitute “forward‐looking statements” and “forward‐looking information,” respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, “expect”,“anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”,“intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements.Forward‐looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including status of patent applications and the ability to secure patents.There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐ looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.